This multicenter, open-label Phase Ib/II study with dose escalation and expansion in Chinese patients with advanced solid tumors consists of Part A (SG1827 plus anti-PD-1/PD-L1) and Part B (SG1827 plus anti-PD-1/PD-L1 and bevacizumab), both evaluating safety, tolerability, PK/PD, immunogenicity, and antitumor efficacy.
Age ≥18 years, male or female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy ≥3 months.
Histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumor. Participants enrolled in the dose escalation phase must have received prior systemic therapy, with disease progression or intolerance to the last line of treatment.
Prior treatment with immunotherapies targeting CTLA 4 and/or CD28 (or agents containing these targets).
Presence of active central nervous system (CNS) metastatic lesions.
Other malignant tumors within 5 years prior to the first dose.
Major surgery (other than diagnostic biopsy) within 28 days prior to the first dose;